between 0.15 and 0.45 cents a share. We will see $15 by then if they can deliver.
150 million shares traded in 2 days between 9.25 and 10. Most investors who bought second offering shares probably sold today to recoup their money. Many shorts have covered and probably going long. New investors came in today and will hold for higher prices. Wall Street is becoming very bullish on JCP. I see $12 by December.
Al Mann will be a Nobel Prize winner within 5 years, hope he is still alive to enjoy it.
BP will have a piece of the action by licensing this technology from Mannkind. Once insulin deal is made, soon I hope, the company will focus and develop that technology. This is a long term hold, hug your shares with both hands.
Very good point, the insulin molecule is a hexamer with each unit 51 amino acid long. What is interesting is that it dissociates into monomers when mixed with the carrier, that's why Afrezza is super fast acting. Most other drugs are smaller than the insulin monomer, so much potential here.
Well said!! Not to mention gastrointestinal side effects and acid reflux with some drugs.
Any drug that will not react with the carrier and maintains pH near 7 in the lungs is a candidate. Hope that helps.
I have a Ph.D. in chemistry specializing in nanotechnology and drug design. Technosphere is a breakthrough technology allowing particles (drugs) captured within the crystal lattice of the carrier to be to passed from the lungs to the bloodstream. The carrier is then expelled from the body without being metabolized. Take a minute to think about this.!!! I invest in Mannkind not for the insulin but for the potential of this technology.This is another Tesla in the making, at first unappreciated but once the market catches up, this stock will fly. I only have 5000 shares now and will add on any drastic drop. i am in long term. Good luck people!!
Apidra, their fast acting insulin is not doing well and Lantus, long acting insulin patent expires next year. They need Afrezza badly. THIS IS A NO BRAINER!!!!
This a recipe for massive short covering on any good news.
Will be back above 11 soon, just be patient and have faith in Mann the man. He is got a $ billion of his money in this.
Pfeffer was also optimistic on MannKind finding a partner to market Afrezza, a deal he hoped would be in place to launch the product late this year or early next. "We have every reason to think we will have a partner," he said.
"There's a lot of upside potential still here," Pfeffer said. "It wouldn't take much of this market to be very, very large in sales," he added.